New Drug Development and Regulation
U-NEURON’s Amniotic Fluid Stem Cell New Drug Secures Dual ExpeditedRegulatory Guidance for Regenerative Medicine
U-NEURON (6973-TW) announced today (22nd) that its proprietary new drug candidate UA002, designed for the treatment of erectile dysfunction, has been approved by Taiwan TFDA under the "Project-Based Advisory and Guidance Cases" scheme. Concurrently, UA002 secured the "Flagship Project" (Index Case) qualification from the Center for Drug Evaluation (CDE). Under this dedicated advisory framework, the company expects to accelerate development and regulatory review while mitigating R&D risks, marking dual expeditedregulatory support in the regenerative medicine arena.
U-NEURON Targets Multi-Billion ED Blue Ocean Market, Launching Dual-Engine Growth in Healthcare and Aesthetics
U-NEURON Chairman Dr. Frank Chien Projects Turnaround to Profitability Next Year
Pioneering Patented Amniotic Fluid Stem Cell Technology! Targeting a Multi-Billion-Dollar Market, U-NEURON Chairman States: “Anyone Dissatisfied with Viagra Is Our Customer”
U-NEURON (6973) leverages its world-leading patented amniotic fluid stem cell technology to address the multi-billion-dollar blue ocean market of male erectile dysfunction (ED).
U-NEURON’s ED Drug UA002 Validates Phase 1 Safety Profile
U-NEURON (6973), a biotech companylistedon Taiwan’s Emerging Stock Market, announced on the 3rd that Phase 1 clinical trial enrollment for its novel therapeutic UA002, targeting male erectile dysfunction (ED), has been completed, with Phase 2 trials set to commence.